Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hepatobiliary Cancers × durvalumab × Gastrointestinal × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 57 Biliary Tract Neoplasms 29 Colorectal Neoplasms 26 Cholangiocarcinoma 26 Pancreatic Neoplasms 22 Liver Neoplasms 17 Stomach Neoplasms 12 Esophageal Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Breast Neoplasms 10 Gallbladder Neoplasms 9 Esophageal Squamous Cell Carcinoma 8 Adenocarcinoma Of Esophagus 8 Ovarian Neoplasms 7 Melanoma 7 Squamous Cell Carcinoma of Head and Neck 6 Small Cell Lung Carcinoma 6 Neoplasm Metastasis 6 Carcinoma 6 Bile Duct Neoplasms 6 Triple Negative Breast Neoplasms 5 Rectal Neoplasms 5 Carcinoma, Renal Cell 5 Prostatic Neoplasms 4 Lung Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Colonic Neoplasms 4 Adenocarcinoma 4 Uterine Cervical Neoplasms 3 Carcinoma, Merkel Cell 3

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06252753 2025-12-26

LIVER-R

AstraZeneca

Gastrointestinal

Hepatobiliary Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡